Skip to main content

Table 1 ICER (USD at 2018 price levels) (Assuming 25% of non-UAI get PrEP of whom 75% of stop using condoms)

From: Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel

 Without PrEPWith PrEPChange
Assuming four years background decrease in HIV incidence of 5.2%
 HIV cases1113621−493
 DALY losses36512035−1616
 Extra Costs or Savings (−)
Costs
 Intervention1,897,994,1851,897,994,185
 Treatment Costs574,205,146320,086,559−254,118,587
 Productivity Losses176,601,30798,445,173−78,156,144
 Premature Burial4,796,7482,673,913−2,122,835
 TOTAL755,603,2012,319,199,8201,563,596,619
Incremental Cost-Effectiveness Ratio (USD per DALY) 967,744
Assuming eight years background decrease in HIV of 5.2%
 HIV Cases1037578− 459
 DALY losses34221908− 1515
 Extra Costs or Savings (−)
Total Costs708,287,1602,292,823,8021,583,536,642
Incremental Cost-Effectiveness Ratio (USD per DALY) 1,046,219
Assuming no further background decrease in HIV
 HIV Cases1308729− 579
 DALY losses42642377− 1887
 Extra Costs or Savings (−)
Total Costs882,406,4792,389,885,3741,507,478,895
Incremental Cost-Effectiveness Ratio (USD per DALY) 798,876
  1. Note: Assumes 80% PrEP take up by high-risk MSM,
  2. 25% PrEP take up by low-risk MSM of whom 75% stop condom use
  3. PrEP efficacy of 86.0% (molina, mccormack)
  4. Based on MOH payment schedule to HMOs for HIV/AIDS patients
  5. A 10% discount on current PrEP prices